GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2009

Crucell Taps Calmune for Discovery Work in Infectious Diseases

  • Calmune and Crucell inked a deal focusing on research, development, production, and marketing of vaccines, proteins, and antibodies that prevent and/or treat infectious diseases. Calmune will use its SEBVI™ technology to prepare a panel of potent, high-affinity human mAbs against a predefined target.

    Crucell will have the option to exclusively license these mAbs for further evaluation and development. Calmune will receive payments from Crucell at different stages of the discovery and development process as well as a royalty on sales of products that incorporate antibodies generated by Calmune.

    SEBVI reportedly allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?